Pharmaceutical giant Allergan Aesthetics, an AbbVie company and the brand behind Botox, has announced that the European Commission (EC) has approved trenibotulinumtoxinE ‘Boey’ in Europe.
Allergan says that Boey is the first rapid-onset and short-duration botulinum neurotoxin serotype E approved in Europe for the temporary improvement of frown lines/glabellar lines in adult patients.
The company shares that results may be seen as early as eight hours after treatment and typically wear off within two to three weeks. The company says that Boey offers a differentiated treatment option for those curious about facial injectables, but perhaps not ready to commit.
This EC approval follows approval in Canada in June 2026.
Darin Messina, senior vice president and global head of aesthetics research and development at AbbVie, commented: “The EU approval of Boey marks an important step forward for our development programme and builds on the momentum we’ve established with Health Canada’s approval earlier this year. This milestone reflects the scientific rigor behind Boey and reinforces our commitment to advancing innovative options as we work to bring this treatment to healthcare.”
